FDA Grants Endostart’s Endorail with 510(k) Clearance

Endostart has received FDA 510(k) clearance for its flagship product, Endorail. This marks a significant step forward in advancing gastrointestinal endoscopy and improving patient care.
 
Endorail is commercially available in the US and it enhances the safety and efficiency of endoscopic procedures, serving as a solution to solve looping and facilitate prolonged colonoscopies. It is designed to streamline the colonoscopy process with its magnetic balloon solution and user-friendly features that empower physicians to overcome procedural challenges. 
 
Endorail helps physicians gain access to an on-demand tool that optimizes procedural outcomes and reduces healthcare costs associated with prolonged or incomplete procedures. 
 
“We are thrilled to obtain FDA clearance for Endorail, marking a significant milestone in our journey to revolutionize gastrointestinal endoscopy,” said Dr. Alessandro Tozzi, Endostart co-founder and CEO. “This clearance underscores our commitment to innovation and our dedication to improving patient care. We look forward to introducing Endorail to endoscopic centers across the United States, empowering physicians with the tools they need to deliver exceptional care.”
 
The company conducted a multicenter clinical trial in 2023, demonstrating the safety and efficiency profile of Endorail in completing difficult colonoscopies. Endostart will share these results at the Digestive Disease Week Congress in Washington DC on May 18-21, 2024.
 
“Through this study, Endostart and our research partners have established that Endorail is safe and can be used effectively on demand in patients with prolonged colonoscopies. Future studies will be carried out to identify additional benefits, including cost advantages and time-saving with our device,” Dr. Tozzi added.
 
This FDA clearance positions the company to expand in the United States and offer its solutions to more healthcare providers and patients. In leveraging its magnetic balloon technology, Endostart intends to position itself as a leader in endoscopic solutions.